• Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

    المصدر: Nasdaq GlobeNewswire / 22 أغسطس 2022 06:00:00   America/Chicago

    STAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session at the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held September 7-10, 2022, in Milan, Italy.

    Details of the late-breaking oral presentation are as follows:

    Title: A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
    Session: D1T01.3: Late breaking news
    Session Date and Time: September 8, 2022, 14.15-17.30 CEST
    Presenter: Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY

    About Cara Therapeutics

    Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

    MEDIA CONTACT:
    Annie Spinetta
    6 Degrees
    973-768-2170
    aspinetta@6degreespr.com

    INVESTOR CONTACT:
    Iris Francesconi, Ph.D.
    Cara Therapeutics
    203-406-3700
    investor@caratherapeutics.com


    Primary Logo

شارك على،